D-1455-2019 Class II Ongoing

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1455-2019 was initiated by Teva Pharmaceuticals USA on Jun 6, 2019 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is ongoing. Affected quantity: 2,924,000 tablets.

Recall details

Product Type
Drugs
Report Date
Jul 17, 2019
Initiation Date
Jun 6, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,924,000 tablets

Product description

LOSARTAN POTASSIUM 50 mg TABLET BULK 90 count bottles and 1000 count bottles, NDC 00591-3746-00

Reason for recall

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Distribution pattern

Nationwide by 4 major distributors.

Code information

Arrow Malta (Teva) Bulk Product Lot # 1169752A, exp. date 01/2020, 1000 tablets/bottle 1169753A, exp. date 01/2020, 90 tablets/bottle Golden State Medical Finished Product Lot # GS017387, exp. date 01/2020 GS017651, exp. date 01/2020 GS017479, exp. date 01/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1455-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1455-2019. Report a data issue: hello@regdatalab.com.